6 September, 2022
aptaTargets has been invited to participate at the 2nd Annual Oligonucleotide Therapeutics & Delivery Conference, focused on the latest developments in oligonucleotide therapeutics and advancements in oligonucleotide delivery, which take place on 21-22 September 2022 in London.
Dr Macarena Hernández, Chief Scientific Officer of aptaTargets, will give a talk about the clinical development of ApTOLL and its potential to reduce inflammation, on 22 September at 9:50 am.
ApTOLL is a first-in-class single-strand DNA molecule (aptamer) discovered and developed by aptaTargets to block TLR4 as a crucial receptor involved in the inflammatory response triggered in different diseases.
During the talk, Dr Hernández will present results of safety and efficacy of ApTOLL including preclinical data in intracerebral hemorrhage, myocardial infarction and multiple sclerosis as well as clinical trials in healthy volunteers in acute ischemic stroke and COVID-19 patients.
For more information, please visit www.oligonucleotide.co.uk